Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published today in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years
/PRNewswire/ Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that.
/PRNewswire/ The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK).
Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta Rhecogen , a subsidiary focused on mRNA vaccines of the infectious diseases, launched the world's first lyophilized mRNA vaccine TAIZHOU, China, Jan. 17, 2022 /PRNewswire/ The.